Jump Financial, LLC Viking Therapeutics, Inc. Transaction History

Jump Financial, LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$49.84 - $70.47 $328,644 - $464,679	-6,594 Closed	0 $0
Q2 2024 Aug 14, 2024	BUY	$47.39 - $80.2 $312,489 - $528,838	6,594 New	6,594 $349,000
Q4 2023 Oct 21, 2024	SELL	$9.24 - $19.64 $1.37 Million - $2.92 Million	-148,600 Reduced 81.45%	33,837 $629,000
Q4 2023 Feb 07, 2024	SELL	$9.24 - $19.64 $1.37 Million - $2.92 Million	-148,600 Reduced 81.45%	33,837 $629,000
Q3 2023 Oct 21, 2024	BUY	$10.92 - $16.0 $1.92 Million - $2.81 Million	175,843 Added 2666.71%	182,437 $2.02 Million
Q3 2023 Nov 07, 2023	BUY	$10.92 - $16.0 $1.99 Million - $2.92 Million	182,437 New	182,437 $2.02 Million
Q4 2022 Feb 13, 2023	SELL	$2.72 - $9.4 $8,704 - $30,080	-3,200 Reduced 5.33%	56,800 $533,000
Q3 2022 Nov 07, 2022	BUY	$2.55 - $3.89 $153,000 - $233,400	60,000 New	60,000 $163,000
Q2 2022 Aug 09, 2022	SELL	$2.11 - $3.15 $117,913 - $176,031	-55,883 Closed	0 $0
Q1 2022 May 12, 2022	BUY	$3.0 - $4.88 $167,649 - $272,709	55,883 New	55,883 $168,000
Q4 2021 Feb 10, 2022	SELL	$4.6 - $6.72 $49,679 - $72,576	-10,800 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$5.58 - $7.04 $60,264 - $76,032	10,800 New	10,800 $68,000

473

66.2M

5.72M

3.39M

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $3.95B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of Jump Financial, LLC, based on Form 13F filings with the SEC.

Stay updated on Jump Financial, LLC with notifications on news.